Drug Approval Milestone
Wockhardt’s Zaynich Gets Positive CDSCO Panel Nod for Gram-Negative Infections
NSE
wockpharma
BSE
532300
Wockhardt’s novel antibiotic Zaynich (Zidebactam/Cefepime) has received a favourable recommendation from CDSCO’s Subject Expert Committee (SEC), moving closer to final approval in India.
PRICE-SENSITIVE TRIGGER
Event: Positive Regulatory Recommendation (CDSCO SEC)
Type: Drug Approval Milestone
Impact: Positive
Immediate Effect: Clears path for final approval by DCGI, Strengthens Wockhardt’s pharma pipeline.
Target Market
Gram-negative infections
Global Status
US & EU fillings submitted
Drug Name
Zaynich (Zidebactam/Cefepime)
Stage
SEC Recommended (Pre-final approval)
What Happened ?
Wockhardt received:
- Favourable recommendation from CDSCO’s Subject Expert Committee
- For marketing approval of its novel antibiotic Zaynich
Final approval from DCGI (Drugs Controller General of India)
Detailed breakdwon
Drug Significance
- Targets:
- Multi-drug resistant (MDR)
- Extensively drug-resistant (XDR) infections
Clinical Strength
- Phase 1: Conducted in US & China (~300 patients)
- Phase 2: Meropenem-resistant infections
- Phase 3:
- 530 patients
- 64 global sites
Real-World Performance
- 97% clinical efficacy in resistant infections
- Strong outcomes in:
- Pneumonia (HABP/VABP)
- Bloodstream infections
- cUTI & intra-abdominal infections
Global Progress
- US: NDA filed
- EU: MAA filed
- Both in advanced stages
Innovation Edge
- Novel β-lactam enhancer mechanism
- Potential to address global antibiotic resistance crisis
Management commentary
- Product backed by 15+ years of R&D
- Supported by global clinical studies
- Positioned as a major innovation in antibiotics
Risk Analysis
Key Risks
- Final approval pending (DCGI)
- Commercial execution challenges
- Pricing/regulatory constraints
Worst Case Scenario
Delay or rejection in final approval
Risk Level: Medium
Reason: Strong data, but regulatory dependency remains
Official Exchange Filing: Click Me